logo
ProjectEnded

ONCOlogic patient profiling and personalized treatment through SMART bedside diagnostics

One of 10,000+ projects Taiyo tracks in Italy.

Source: EU Funding & Tenders Portal

ONCOSMART is the first In-Vitro Diagnostic (IVD) system that determines the effectiveness of anticancer drugs for a specific patient, testing live cell response to one or multiple cancer drugs. ONCOSMART analyses bone marrow or blood samples from a specific cancer patient, providing the results within 24-48 hours. This “functional profiling” approach has shown superior performance in non-automated

Status
Closed
Sector
Power Generation (CCGT)
Location
Italy
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about ONCOlogic patient profiling and personalized treatment through SMART bedside diagnostics

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “ONCOlogic patient profiling and personalized treatment through SMART bedside diagnostics” is an infrastructure initiative in the Power Generation (CCGT) sector, located in Italy. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

ONCOSMART is the first In-Vitro Diagnostic (IVD) system that determines the effectiveness of anticancer drugs for a specific patient, testing live cell response to one or multiple cancer drugs. ONCOSMART analyses bone marrow or blood samples from a specific cancer patient, providing the results within 24-48 hours. This “functional profiling” approach has shown superior performance in non-automated systems to current molecular/genomic methods in predicting individual patient’s response to anticancer treatments. ONCOSMART is a fully-automated and standardised functional profiling platform that is made available to doctors and researchers to identify the most suitable cancer therapy for individual patients and also aid patient selection in clinical trials. The innovative platform analyses the interactions between anticancer drugs and live tumor cells contained in 2 mL of blood or bone marrow samples. Cellply has freedom to operate and protected ONCOSMART with 2 patent families issued in EU, US and China, 1 issued in EU, 1 pending PCT application, 2 pending Italian applications. Additional value is captured by 4 patent applications to be submitted in 2018-2019. ONCOSMART can test anticancer drugs including targeted, chemo and immunotherapies alone or in combination. The test results guide the selection of: 1) the appropriate therapy for a specific patient; 2) cancer patients for specific clinical studies; 3) cancer patients for novel therapies in clinical development. The platform has been fully-engineered and tested on leukemia patients (AML), proving its predictive power, and is extended to other hematologic and solid tumors in future developments. Within this project, CellPly has the goal to industrialise the platform, validate its analytical and clinical performance and support the first commercialisation activities releasing the platform for research first, then for clinical use.

Location

Country

Italy

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Power Generation (CCGT)

Article published date

2026-02-01

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project